Lilly rival gets FDA okay for Phase 2 study of obesity drug

China’s Gan & Lee Pharmaceuticals has received FDA clearance to run a head-to-head Phase 2 study of its drug candidate GZR18 Injection against Eli Lilly’s (NYSE:LLY) weight-loss drug tirzepatide, also known as Zepbound and Mounjaro.

Gan & Lee said the study will